Leadership is solving problems - Colin Powell
Investment Thesis
In 2015, the stock price of Genfit (GNFTF) stumbled on the release of the top line data of the Phase 2b GOLDEN-505 study of elafibranor therapy in NASH due to misinterpretation of the results. However, reanalysis of the data using the newly adopted Joint AASLD-FDA 2013 regulatory guidance revealed that elafibranor at the higher dose was more therapeutically effective than placebo at causing NASH histological resolution without fibrosis worsening. Phase 2b preliminary data was clinically successful since the clinical endpoint was achieved.
Genfit’s Phase 3 hypothesis